StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
JPMorgan First Take on Biogen (BIIB)
April 24, 2024 9:06 AM
JPMorgan analyst Chris Schott reiterated a Neutral rating on Biogen (NASDAQ: BIIB).The analyst comments "This morning, BIIB reported 1Q results ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Biogen (BIIB) PT Lowered to $317 at RBC Capital
April 25, 2024 6:39 AM
BMO Capital First Take on Biogen (BIIB) Earnings
April 24, 2024 7:57 AM
Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
April 24, 2024 7:43 AM
Form 8-K BIOGEN INC. For: Apr 24
April 24, 2024 7:03 AM
Biogen (BIIB) tops earnings expectations but revenue falls short
April 24, 2024 7:02 AM
Biogen cost cuts drive profit beat, as Alzheimer's drug off to slow start
April 24, 2024 6:48 AM
Biogen (BIIB) Tops Q1 EPS by 24c; reaffirms guidance
April 24, 2024 6:46 AM
Biogen (BIIB) April weekly option implied volatility into quarter results
April 23, 2024 11:07 AM
